| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/03/2008 | US20080081781 Methods and compositions for the treatment of metabolic syndrome |
| 04/03/2008 | US20080081780 Identification of oligoadenylate synthetase-like genes |
| 04/03/2008 | US20080081373 Genetic inhibition by double-stranded RNA |
| 04/03/2008 | US20080081355 Activatable recombinant neurotoxins |
| 04/03/2008 | US20080081082 Topical Skin Compositions, Their Preparation, and Their Use |
| 04/03/2008 | US20080081080 Antibacterial zeolite, oil, and glutathione and/or L-cysteine; aluminum chlorhydroxide powder; washability when it has adhered to clothing |
| 04/03/2008 | US20080081078 Administering an enzyme inhibibitor to cause reduction in myosin light chain phosphorylation and to induce apoptosis in tumor cells; breast cancer, prostate cancer, lung carcinoma, renal cell carcinoma, glioma, melanoma, chemotherapy resistant tumors or metastatic tumors |
| 04/03/2008 | US20080081077 Method of wound/burn healing using copper-zinc compositions |
| 04/03/2008 | US20080081074 Polymers for functional particles |
| 04/03/2008 | US20080081064 Drug delivery of two or more drugs (hydrophilic and hydrophobic); arranged within inner space of body member of biodegradable polysaccharide so that each drug in the inner space is individually releasable through their respective aperture set; eye caps |
| 04/03/2008 | US20080081060 Chitosan-coated calcium sulfate based medicament delivery system |
| 04/03/2008 | US20080081050 Vaccine against streptococcus pneumoniae |
| 04/03/2008 | US20080081049 Treatment of fine wrinkles with clostridia neurotoxins |
| 04/03/2008 | US20080081043 Nucleotide sequences coding natural killer cell ligand for use as tool in treatment cell proliferative disorders |
| 04/03/2008 | US20080081036 Using topical mixture to repair and condition animal skin |
| 04/03/2008 | US20080081035 Therapeutic protease compositions |
| 04/03/2008 | US20080081034 Topical Skin Compositions, Their Preparation, and Their Use |
| 04/03/2008 | US20080081031 Using polyethylene glycol conjugated interleukin-10 as antitumor agent in treatment of cell proliferative disorders |
| 04/03/2008 | CA2664921A1 N-terminal fgf variants having increased receptor selectivity and uses thereof |
| 04/03/2008 | CA2664795A1 Therapeutic compositions to improve the effect of the therapy with anti-epidermal growth factor receptor antibodies |
| 04/03/2008 | CA2664558A1 Analogs of ghrelin substituted at the n-terminal |
| 04/03/2008 | CA2664359A1 Cytokine signaling |
| 04/03/2008 | CA2663789A1 Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| 04/02/2008 | EP1905844A2 Application of mRNA for use as a therapeutic agent against tumours |
| 04/02/2008 | EP1905834A2 Virulence Genes, Proteins, and their Use |
| 04/02/2008 | EP1905832A2 Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 04/02/2008 | EP1905831A2 Lactoferrin receptor genes of moraxella |
| 04/02/2008 | EP1905830A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/02/2008 | EP1905782A1 Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| 04/02/2008 | EP1905780A1 Cancer suppressing agent |
| 04/02/2008 | EP1905779A1 Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same |
| 04/02/2008 | EP1905457A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 04/02/2008 | EP1905448A2 Selection of patients with increased responsiveness to botulinum toxin |
| 04/02/2008 | EP1905447A2 Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha |
| 04/02/2008 | EP1905446A1 Use of PYY analogs and antagonists of PPY receptors for manipulating satiety |
| 04/02/2008 | EP1905445A1 Tumor growth inhibitor |
| 04/02/2008 | EP1905438A2 Hypoglycemic agent |
| 04/02/2008 | EP1905436A1 Synergistic time-delaying agent for local anestheic |
| 04/02/2008 | EP1905357A1 Method of imaging cell death in vivo |
| 04/02/2008 | EP1905309A1 Uses of oil bodies |
| 04/02/2008 | EP1905304A2 Treatment of neoplasms with viruses |
| 04/02/2008 | EP1904844A2 Compositions and methods for enhancing axon regeneration |
| 04/02/2008 | EP1904635A2 Glycosylated il-7, preparation and uses |
| 04/02/2008 | EP1904527A2 Identification of a novel bitter taste receptor t2r76 that specifically responds to brucine and prop bitter ligands |
| 04/02/2008 | EP1904523A1 Defensin proteins |
| 04/02/2008 | EP1904516A2 Hepatitis c virus inhibitors |
| 04/02/2008 | EP1904183A2 Imaging and therapeutic method using monocytes |
| 04/02/2008 | EP1904108A2 Formulation and method for administration of ophthalmologically active agents |
| 04/02/2008 | EP1904095A1 Treatment of liver cirrhosis and its complications |
| 04/02/2008 | EP1904094A2 Use of vegf for wound healing |
| 04/02/2008 | EP1904093A2 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| 04/02/2008 | EP1904092A2 Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease |
| 04/02/2008 | EP1904091A2 Compositions and methods for suppressing axonal growth inhibition |
| 04/02/2008 | EP1904090A2 Bone morphogenetic protein formulations |
| 04/02/2008 | EP1904089A2 Promotion of epithelial regeneration |
| 04/02/2008 | EP1904088A2 Compositions and methods for the treatment of cancer |
| 04/02/2008 | EP1904087A2 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| 04/02/2008 | EP1904086A2 Treatment of tumors |
| 04/02/2008 | EP1904085A2 Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke |
| 04/02/2008 | EP1904084A2 Methods of protecting against apoptosis using lipopeptides |
| 04/02/2008 | EP1904083A2 Synapse-specific proteins in glomeruli |
| 04/02/2008 | EP1904082A2 Method for determining the concentration of the adipocytic form of the fatty acid binding protein (a-fabp, fabp4, p2) |
| 04/02/2008 | EP1904081A2 Compositions and methods to control angiogenesis with cupredoxins |
| 04/02/2008 | EP1904080A1 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage |
| 04/02/2008 | EP1904078A1 Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds |
| 04/02/2008 | EP1904076A1 Cell nucleus-entering compositions |
| 04/02/2008 | EP1903895A2 Calcium-peptide component |
| 04/02/2008 | EP1903874A2 Aav vectors encoding superoxide dismutase |
| 04/02/2008 | EP1750737A4 Improved method for identifying peptides in a biological sample |
| 04/02/2008 | EP1701733B1 Surface protection of exposed biological tissues |
| 04/02/2008 | EP1682664A4 Methods for the production of apolipoproteins in transgenic plants |
| 04/02/2008 | EP1424898A4 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 04/02/2008 | EP1397153B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 04/02/2008 | EP1274729B1 G protein coupled receptor |
| 04/02/2008 | EP1244466B1 ACTIVATION OF THE IMMUNE SYSTEM BY AN NF-kappaB INDUCER AND AN ANTIGEN |
| 04/02/2008 | EP1091729B1 Spray-dried microparticles of insulin for inhalation |
| 04/02/2008 | EP1009824B1 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-kappaB ACTIVATION |
| 04/02/2008 | EP0964692B1 Use of glp-1 or analogs in treatment of myocardial infarction |
| 04/02/2008 | EP0822985B1 Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| 04/02/2008 | EP0822830B1 Human anti-IL-8 antibodies, derived from immunized xenomice |
| 04/02/2008 | EP0815245B1 Bioactive il-12 fusion proteins |
| 04/02/2008 | EP0666911B1 Multidrug resistance gene |
| 04/02/2008 | CN101155916A Targeted plasminogen activator fusion proteins as thrombolytic agents |
| 04/02/2008 | CN101155829A High affinity HIV T cell receptors |
| 04/02/2008 | CN101155827A HIV resistance genes |
| 04/02/2008 | CN101155825A Antimicrobial hexapeptides |
| 04/02/2008 | CN101155602A Caspase-3 substrate comprising imaging agents |
| 04/02/2008 | CN101155596A Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |
| 04/02/2008 | CN101155595A Antitumor agent and dnase |
| 04/02/2008 | CN101153056A Regrouped anticancer peptide, producing method and application of the same |
| 04/02/2008 | CN101153055A Novel peptide with angiotonin transferase restraining liveness and method of producing the same |
| 04/02/2008 | CN101153054A Peptide for treatment of vascellum generation and uses thereof |
| 04/02/2008 | CN101153053A Bone-peptide, producing method, pharmaceutical composition and uses thereof |
| 04/02/2008 | CN101153052A Uridine peptide antibiotic, pharmaceutically acceptable salt, producing method and uses thereof |
| 04/02/2008 | CN101152574A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/02/2008 | CN101152573A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/02/2008 | CN101152569A Pharmaceutical composition having preventing, protecting and treating functions for myocardial ischemia and oxygen deficiency type damnification |
| 04/02/2008 | CN101152568A Polypeptide combination preparations having functions of accelerating angiogenesis, organ reactivation and wound healing |
| 04/02/2008 | CN101152567A Medicament combination for regrouping human interleukin-11 |
| 04/02/2008 | CN101152566A Medicament combination of human keratinized cell growth factor for treating alopecia |